cervical cancer stage II-IV Cervical Neoplasms / drug therapy Cisplatin / adverse effects Hydration Therapy / methods Creatinine / blood
Conditions
Interventions
After chemotherapy, this group received an additional 1000 mL of NSS with 10 mEq KCl intravenously over a two-hour period.,After chemotherapy, this group was instructed to consume 1000 mL of drinking
IV Hydration,Oral Hydration
Sponsors
Songklanagarind Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Newly diagnosed patients with pathologically proven Squamous cell carcinoma or Adenocarcinoma, classified as Stage II or III according to the International Federation of Gynecology and Obstetrics (FIGO) staging system, without obstructive uropathy, and who are being treated with concurrent chemoradiotherapy. 2.Patients have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
Exclusion criteria
Exclusion criteria: 1. The patient declined to continue/follow up with the treatment. 2. Female patients with a pre-treatment serum creatinine level greater than or equal to 1.2 mg/dL. 3. Patients with abnormal vital signs before, during, or after receiving medication, such as: Low blood pressure (hypotension) below 90/60 mmHg. Rapid heart rate (tachycardia) faster than 100 beats per minute. Rapid breathing (tachypnea) faster than 25 breaths per minute. Fever (elevated body temperature) higher than 38 C. 4. Patients with a history of underlying diseases, including heart, kidney, or liver disease/dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum creatinine 48 hour mg% | — |
Secondary
| Measure | Time frame |
|---|---|
| Electrolyte Abnormalities 48 hr potassium, magnesium levels,Hematologic Toxicities 48 hr white blood cell count, platelet count, anemia | — |
Countries
Thailand
Contacts
Public ContactRakchai Buhachat
Prince of Songkhla University
Outcome results
None listed